These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21111542)

  • 21. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
    Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroconversion of puppies to canine parvovirus and canine distemper virus: a comparison of two combination vaccines.
    Coyne MJ
    J Am Anim Hosp Assoc; 2000; 36(2):137-42. PubMed ID: 10730624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
    Siedek EM; Schmidt H; Sture GH; Raue R
    Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Case report: effect of maternal antibodies on the vaccination against canine parvovirus].
    Schunck B; Truyen U
    Tierarztl Prax; 1995 Apr; 23(2):185-6. PubMed ID: 7624862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs.
    Freisl M; Speck S; Truyen U; Reese S; Proksch AL; Hartmann K
    Vet J; 2017 Jan; 219():15-21. PubMed ID: 28093104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure?
    Altman KD; Kelman M; Ward MP
    Vet Microbiol; 2017 Oct; 210():8-16. PubMed ID: 29103701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thoughts on vaccination protocols.
    Petzel B
    J Am Vet Med Assoc; 2000 Nov; 217(10):1459. PubMed ID: 11128531
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of antibodies to canine parvovirus and reaction to vaccination in client-owned, healthy dogs.
    Riedl M; Truyen U; Reese S; Hartmann K
    Vet Rec; 2015 Dec; 177(23):597. PubMed ID: 26514756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thoughts on vaccination protocols.
    McLaughlin MA
    J Am Vet Med Assoc; 2000 Nov; 217(10):1458-9. PubMed ID: 11128530
    [No Abstract]   [Full Text] [Related]  

  • 30. Serological survey of canine parvovirus 2 antibody titres in breeding kennels in northern Italy.
    Rota A; Dogliero A; Muratore E; Pregel P; Del Carro A; Masoero L
    BMC Vet Res; 2019 Sep; 15(1):335. PubMed ID: 31533724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Immunity and Seropositivity of IgG Antibodies to Canine Parvoviruses in Vaccinated and Unvaccinated Dogs in Abeokuta, Nigeria.
    Babalola ET; Ijaopo OK; Okonko IO
    J Immunoassay Immunochem; 2016; 37(1):16-28. PubMed ID: 25891124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of vaccination against canine parvovirus.
    Thompson H
    Vet Rec; 2006 Oct; 159(17):570-1; discussion 571. PubMed ID: 17056657
    [No Abstract]   [Full Text] [Related]  

  • 33. Evolution of canine parvovirus--a need for new vaccines?
    Truyen U
    Vet Microbiol; 2006 Oct; 117(1):9-13. PubMed ID: 16765539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serologic response of pups to the low-passage, modified-live canine parvovirus-2 component in a combination vaccine.
    O'Brien SE
    J Am Vet Med Assoc; 1994 Apr; 204(8):1207-9. PubMed ID: 8014088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of immune status in dogs against CPV-2 by recombinant protein based latex agglutination test.
    Thomas J; Singh M; Goswami TK; Glora P; Chakravarti S; Chander V; Upmanyu V; Verma S; Sharma C; Mahendran K
    Biologicals; 2017 Sep; 49():51-56. PubMed ID: 28689674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
    Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
    Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay.
    Waner T; Naveh A; Wudovsky I; Carmichael LE
    J Vet Diagn Invest; 1996 Oct; 8(4):427-32. PubMed ID: 8953526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain.
    Pratelli A; Altamura M; Buonavoglia D; Pepe M; Tafaro A; Lembo A; Cirone F; Tempesta M; Jirillo E; Buonavoglia C
    Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):451-64. PubMed ID: 10946825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication?
    Decaro N; Buonavoglia C; Barrs VR
    Vet Microbiol; 2020 Aug; 247():108760. PubMed ID: 32768213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination at different anatomic sites induces different levels of the immune responses.
    Jin H; Xu Y; Shi F; Hu S
    Res Vet Sci; 2019 Feb; 122():50-55. PubMed ID: 30453180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.